Press Release Archive

PAN-TB Collaboration to Advance Investigational Tuberculosis Drug Regimens to Phase 2 Clinical Trials

PAN-TB Collaboration to Advance Investigational Tuberculosis Drug Regimens to Phase 2 Clinical Trials

Public-private collaboration to evaluate five antimicrobial agents across two combination regimens for treating both drug-susceptible and drug-resistant forms of TB with shorter treatment durations

Media Statement August 11, 2022

Johnson & Johnson Consumer Health to Transition Global Baby Powder Portfolio to Cornstarch

Johnson & Johnson Consumer Health to Transition Global Baby Powder Portfolio to Cornstarch

Johnson & Johnson to Participate in the Morgan Stanley 20^th Annual Global Healthcare Conference

Johnson & Johnson to Participate in the Morgan Stanley 20^th Annual Global Healthcare Conference

Mathai Mammen, M.D., Ph.D., Leaves Position as Executive Vice President, Pharmaceuticals, R&D, Johnson & Johnson

Mathai Mammen, M.D., Ph.D., Leaves Position as Executive Vice President, Pharmaceuticals, R&D, Johnson & Johnson

European Commission Approves IMBRUVICA^® (ibrutinib) in a Fixed-Duration Combination Regimen for Adult Patients with Previously Untreated Chronic Lymphocytic Leukaemia (CLL)

European Commission Approves IMBRUVICA^® (ibrutinib) in a Fixed-Duration Combination Regimen for Adult Patients with Previously Untreated Chronic Lymphocytic Leukaemia (CLL)

Approval marks the first all-oral, once-daily, fixed-duration Bruton’s tyrosine kinase (BTK) inhibitor-based regimen for first-line treatment of CLL

Johnson & Johnson to Participate in the 2022 Wells Fargo Securities Healthcare Conference

Johnson & Johnson to Participate in the 2022 Wells Fargo Securities Healthcare Conference

STELARA^® (ustekinumab) Approved by the U.S. Food and Drug Administration to Treat Pediatric Patients with Active Psoriatic Arthritis

STELARA^® (ustekinumab) Approved by the U.S. Food and Drug Administration to Treat Pediatric Patients with Active Psoriatic Arthritis

As the first and only biologic targeting both cytokines interleukin (IL)-12 and IL-23, STELARA provides a new therapeutic option for children six years of age and older living with active psoriatic arthritis

Active psoriatic arthritis in pediatric patients is a rare disease affecting five to eight percent of children and adolescents with chronic inflammatory arthritis*^1-6

Janssen Announces New Data Supporting Safety and Efficacy of RYBREVANT^® and Lazertinib Combination for Patients with Non-Small Cell Lung Cancer and EGFR Mutations

Janssen Announces New Data Supporting Safety and Efficacy of RYBREVANT^® and Lazertinib Combination for Patients with Non-Small Cell Lung Cancer and EGFR Mutations

Presentations at the International Association for the Study of Lung Cancer (IASLC) 2022 World Conference on Lung Cancer (WCLC) Span Relapsed/Refractory Disease and Frontline Treatment in Patients with EGFR-Positive Non-Small Cell Lung Cancer

Janssen Receives Positive CHMP Opinion for Novel Bispecific Antibody TECVAYLI^® (teclistamab) for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma (RRMM)

Janssen Receives Positive CHMP Opinion for Novel Bispecific Antibody TECVAYLI^® (teclistamab) for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma (RRMM)

Teclistamab is the first T-cell redirecting bispecific antibody to receive a positive CHMP opinion for adults with RRMM and highlights Janssen’s commitment to innovation in multiple myeloma

The opinion is based on the MajesTEC-1 study where teclistamab induced durable responses that deepened over time in patients with heavily pretreated RRMM^[1]

Financial July 19, 2022

Johnson & Johnson Reports Q2 2022 Results

Johnson & Johnson Reports Q2 2022 Results

Total sales growth of 3.0% to $24.0 Billion with operational growth of 8.0%* and adjusted operational growth of 8.1%*

Earnings per share of $1.80 decreasing 23.4% and adjusted earnings per share of $2.59 increasing 4.4%*

Company maintaining 2022 full-year guidance at midpoints for adjusted operational sales and adjusted operational earnings per share; strengthening U.S. dollar impacting estimate for reported results

Internet Explorer is no longer supported by this website.

Topic